Antisense compounds targeting genes associated with cystic fibrosis
US10544417B2 · kind B2 · utility
3Cited by
1References
31Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 8, 2017 |
| Grant date | Jan 28, 2020 |
| Priority date | — |
| Expiry date | Dec 8, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/33
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.